page contents
  • Anne

July 2022 Update!

Enhertu has already been approved for HER2 positive MBC patients who relapsed on prior treatment, and is being assessed for HER2 low patients.

HR+, HER2- and TNBC patients have either HER2 low expression (HER2 +1 or HER2 +2) or no HER2 expression (HER2 0).

The randomized DESTINY-Breast04 trial analyzed the efficacy and safety of Enhertu compared with chemotherapy in patients with HR+ HER2-low MBC, and also in TNBC patients with HER2 low disease. The patients were previously treated with 1 or 2 lines of chemotherapy.

The investigators observed a median Progression Free Survival 10.1 months in HR+, HER2 low patients taking Enhertu versus 5.4 months for those taking chemotherapy, and the median Overall Survival was 23.9 months in the Enhertu group compared with 17.5 months in patients taking chemotherapy.

For TNBC patients with HER2 low disease, the median progression-free survival was 8.5 months in the Enhertu arm and 2.9 months in the chemo arm and the median overall survival more than doubled to 18.2 months with Enhertu vs. chemotherapy.

17 views0 comments

Recent Posts

See All

Enhertu, which has shown statistically significant improvement in PFS when compared with Kadcyla (TDM1) as second-line treatment for HER2-positive MBC, has now been FDA-approved for HER2 positive adul

An Experimental Drug Called Elacestrant May be FDA-Approved This Year! Possibly the most pivotal news divulged at the San Antonio Breast Cancer Symposium in Dec. 2021 was a study of an endocrine ther